Biospecimens, biomarkers, and burgeoning data: The imperative for more rigorous research standards

Trends in Molecular Medicine

Volumn 18, Issue 12, 2012, Pages 717-722

  Poste, George ^a  

^a ARIZONA STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER;

EXOME; GENOMICS; HIGH THROUGHPUT SEQUENCING; INFORMATION PROCESSING; INVESTMENT; MEDICAL RESEARCH; PRODUCTIVITY; PROTEOMICS; REVIEW; VALIDATION PROCESS;

BIOLOGICAL MARKERS; MOLECULAR MEDICINE; RESEARCH; RESEARCH DESIGN; SPECIMEN HANDLING; SYSTEMS INTEGRATION; VALIDATION STUDIES AS TOPIC;

EID: 84870245866     PISSN: 14714914     EISSN: 1471499X     Source Type: Journal    
DOI: 10.1016/j.molmed.2012.09.003     Document Type: Review

References (70)

1. Emerging Themes in Human Disease Cell (Special Issue) 2012, 148:1077-1307.
2. Hood L., Friend S.H. Predictive, personalized, preventive, participatory (P4) cancer medicine. Nat. Rev. Clin. Oncol. 2011, 8:184-187.
3. Topol E. The Creative Destruction of Medicine. How the Digital Revolution Will Create Better Health Care 2012, Perseus Books Group.
4. Offit K. Personalized medicine: new genomics, old lessons. Hum. Genet. 2011, 130:3-14.
5. Harris T.J., McCormick F. The molecular pathology of cancer. Nat. Rev. Clin. Oncol. 2010, 7:251-265.
6. Mills G.B. An emerging toolkit for targeted cancer therapies. Genome Res. 2012, 22:177-182.
7. Kelloff G.J., Sigman C.C. Cancer biomarkers: selecting the right drug for the right patient. Nat. Rev. Drug Discov. 2012, 11:201-214.
8. Wang L., et al. Genomics and drug response. N. Engl. J. Med. 2011, 364:1144-1153.
9. Hazelton W.D., Luebeck E.G. Biomarker-based early cancer detection: is it achievable?. Sci. Transl. Med. 2011, 3:107-111.
10. Baudhuin L.M., et al. How novel molecular diagnostic technologies and biomarkers are revolutionizing genetic testing and patient care. Expert Rev. Mol. Diagn. 2012, 12:25-37.
11. Poste G. Bring on the biomarkers. Nature 2011, 469:156-157.
12. Hanash S.M. Why have protein biomarkers not reached the clinic?. Genome Med. 2011, 3:66-67.
13. Begley C.G., Ellis L.M. Raise standards for preclinical cancer research. Nature 2012, 1483:531-533.
14. Poste G., et al. Leveling the playing field: bringing development of biomarkers and molecular diagnostics up to the standards of drug development. Clin. Cancer Res. 2012, 18:1515-1523.
15. Schilsky R.L., et al. Development and use of integral assays in clinical trials. Clin. Cancer Res. 2012, 18:1540-1546.
16. Brooks J.D. Translational genomics: the challenge of developing cancer biomarkers. Genome Res. 2012, 22:183-187.
17. Compton C. Getting to personalized cancer medicine. Taking out the garbage. Cancer 2007, 110:1641-1643.
18. Williams P.M., et al. Bridging the gap: moving predictive and prognostic assays from research to clinical use. Clin. Cancer Res. 2012, 18:1531-1539.
19. Hewitt S.M., et al. Impact of preanalytic factors on the design and application of integral biomarkers for directing therapy. Clin. Cancer Res. 2012, 18:1524-1529.
20. Vaught J. Research and Policy Initiatives in NCI's Office of Biorepositories and Biospecimen Research 2009, http://sigs.nih.gov/trig/Documents/TRIG_091210_Vaught.pdf.
21. Lukk M., et al. A global map of human gene expression. Nat. Biotechnol. 2010, 28:322-324.
22. Simon R.M., et al. Use of archived specimens in evaluation of prognostic and predictive biomarkers. J. Natl. Cancer Inst. 2009, 101:1446-1452.
23. Fullerton S.M., et al. Meeting the governance challenges of next-generation biorepository research. Sci. Transl. Med. 2010, 2:1-4.
24. Srivastava S., et al. Tanslational Research Working Group developmental pathway for specimen-based assessment modalities. Clin. Cancer Res. 2008, 14:5672-5677.
25. Moore H.M., et al. International approaches to advancing biospecimen science. Cancer Epidemiol. Biomarkers Prev. 2011, 20:729-732.
26. Andre F., et al. Biomarker studies: a call for a comprehensive biomarkers study registry. Nat. Rev. Clin. Oncol. 2011, 8:171-176.
27. Derry J.M.J., et al. Developing predictive molecular maps of human disease through community-based modeling. Nat. Genet. 2012, 44:127-130.
28. Clayton G.W., et al. Confronting real time ethical, legal and social issues in the Electronic Medical Records and Genomics (eMERGE) Consortium. Genet. Med. 2010, 12:616-620.
29. Malin B., et al. Technical and policy approaches to balancing patient privacy and data sharing in clinical and translational research. J. Investig. Med. 2010, 58:11-18.
30. Gibbons S.M.C., et al. Governing genetic databases: challenges facing research regulation and practice. J. Law Soc. 2007, 34:163-189.
31. Wolf S.M., et al. Managing incidental findings and research results in genomic research involving biobanks and archived data sets. Genet. Med. 2012, 14:361-384.
32. m.Health. From Smartphones to Smart Systems 2012, HIMSS. R. Krohm, D. Metcalf (Eds.).
33. Thompson M., Werner C. Wireless and mobile monitoring: bringing health care home. Medtech Insight 2011, 13:33-42.
34. Cooper G.M., Shendure J. Needles in stacks of needles: finding disease-causing variants in a wealth of genomic data. Nat. Rev. Genet. 2011, 12:628-640.
35. Roychoudhury S., et al. Personalized oncology through integrative high-throughput sequencing: a pilot study. Sci. Transl. Med. 2011, 3:111ra121.
36. Micheel C.M., et al. Institute of Medicine: Evolution of Translational Omics: Lessons Learned And The Path Forward 2012, National Academies Press.
37. Yachida S., et al. Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature 2010, 467:1114-1117.
38. Hori S.H., Gambhir S.S. Mathematical model identifies blood biomarker-based early cancer detection strategies and limitations. Sci. Transl. Med. 2011, 3:119-127.
39. Henson D.E., Albores-Saavedra J. Pathology of Incipient Neoplasia 2001, Oxford University Press.
40. Welch H.G., Black W.C. Overdiagnosis in cancer. J. Natl. Cancer Inst. 2010, 102:605-613.
41. Elmore J.G., Fletcher S.W. Overdiagnosis in breast cancer screening: time to tackle an underappreciated harm. Ann. Int. Med. 2012, 156:536-537.
42. Chou R., et al. Screening for prostate cancer: a review of the evidence for the U.S. Preventive Services Task Force. Ann. Int. Med. 2011, 155:762-771.
43. Paul S.M., et al. How to improve R&D productivity: the pharmaceutical industry's grand challenge. Nat. Rev. Drug Discov. 2010, 9:203-214.
44. Gerber D.E., Minng J.D. ALK inhibition for non-small cell lung cancer: from discovery to therapy in record time. Cancer Cell 2010, 18:548-551.
45. Flaherty K.T., et al. Inhibition of mutated activated BRAF in metastic melanoma. N. Engl. J. Med. 2010, 363:809-819.
46. Turke A.B., et al. Pre-existence and clonal selection of MET amplification in EGFR mutant NSCLC. Cancer Cell 2010, 17:77-88.
47. Roche-Lestienne C., et al. Several types of mutations can be found in chronic myeloid leukemia patients resistant to ST1571 and they can pre-exist to the onset of treatment. Blood 2002, 100:1014-1018.
48. Gerlinger M., et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N. Engl. J. Med. 2012, 366:883-892.
49. Koh S.S., et al. Differential gene expression profiling of primary cutaneous melanoma and sentinel lymph node metastases. Mod. Pathol. 2012, 25:828-837.
50. Olson E.M., et al. The ethical use of mandatory research biopsies. Nat. Rev. Clin. Oncol. 2011, 8:620-626.
51. Martini M., et al. Targeted therapies: how personal should we go?. Nat. Rev. Clin. Oncol. 2012, 9:87-97.
52. Ciriello G., et al. Mutual exclusivity analysis identifies oncogenic network modules. Genome Res. 2012, 22:398-406.
53. Ransohoff D.F. The process to discover and develop biomarkers for cancer: a work in progress. J. Natl. Cancer Inst. 2008, 100:1419-1420.
54. Ioannidis J.P.A., Panagiotou O.A. Comparison of effect sizes associated with biomarkers reported in highly cited individual articles and in subsequent meta-analyses. JAMA 2011, 305:2200-2210.
55. Poste G. Institute of Medicine National Cancer Policy Forum Workshop on Informatics Needs and Challenges in Cancer Research 2012, http://casi.asu.edu/presentations.
56. Sansome S.A., et al. Toward interoperable bioscience data. Nat. Genet. 2012, 4:121-126.
57. Sorani M.D., et al. Clinical and biological data integration for biomarker discovery. Drug Discov. Today 2010, 15:741-748.
58. Ghosh S., et al. Software for systems biology: from tools to integrated systems. Nat. Rev. Genet. 2011, 12:821-832.
59. Caulfield T., et al. Open science versus commercialization: a modern research conflict?. Genome Med. 2012, 4:17.
60. Editorial If you want reproducible science, the software needs to be open source. Nature 2012, 10.1038/nature10836.
61. Trusheim M.R., et al. Quantifying factors for the success of stratified medicine. Nat. Rev. Drug Discov. 2011, 10:817-833.
62. Canestaro W.J., et al. Healthcare payers: a gate of translational bridge to personalized medicine?. Personal. Med. 2012, 9:73-84.
63. Trosman J.R., et al. Health technology assessment and private payer's coverage of personalized medicine. Am. J. Manag. Care 2011, 17(Suppl. 5):SP53. 185-188.
64. Dancey J.E., et al. Guidelines for the development and incorporation of biomarker studies in early clinical trials of novel agents. Clin. Cancer Res. 2010, 16:1745-1755.
65. Baggerly K., Coombes K.R. What information should be required to support clinical "omics" publications?. Clin. Chem. 2011, 57:688-690.
66. Gallo V., et al. Strengthening the Reporting of Observational Studies in Epidemiology-Molecular Epidemiology (STROBE-ME): an extension of the STROBE statement. PLoS Med. 2011, 8:e100117.
67. Bossuyk P.M., et al. The STARD statement for reporting studies of diagnostic accuracy: explanation and elaboration. Clin. Chem. 2003, 49:1-6.
68. Khleif S.N., et al. AACR-FDA-NCI Cancer Biomarkers Collaborative Consensus Report: advancing the use of biomarkers in cancer drug development. Clin. Cancer Res. 2010, 16:3299-3318.
69. Grossman C., et al. Institute of Medicine. Digital Infrastructure for the Learning Health System 2011, National Academies Press.
70. National Science Foundation Cyberinfrastructure for 21st Century Science and Engineering (CIF21). Advanced Computing Infrastructure. Vision and Strategic Plan 2012, http://www.nsf.gov/pubs/2012/nsf12051/nsf12051.pdf.